NASDAQ:TENX Tenax Therapeutics (TENX) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free TENX Stock Alerts $3.56 +0.06 (+1.71%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$3.48▼$3.6350-Day Range$3.53▼$5.0152-Week Range$3.48▼$61.20Volume7,881 shsAverage Volume284,180 shsMarket Capitalization$6.98 millionP/E RatioN/ADividend YieldN/APrice Target$480.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Tenax Therapeutics alerts: Email Address Tenax Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside13,383.1% Upside$480.00 Price TargetShort InterestHealthy2.62% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($7.43) to ($3.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.39 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTenax Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTenax Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.62% of the float of Tenax Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenax Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tenax Therapeutics has recently increased by 33.51%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTenax Therapeutics does not currently pay a dividend.Dividend GrowthTenax Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TENX. Previous Next 3.0 News and Social Media Coverage News SentimentTenax Therapeutics has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tenax Therapeutics this week, compared to 1 article on an average week.Search Interest13 people have searched for TENX on MarketBeat in the last 30 days. This is an increase of 63% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tenax Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.85% of the stock of Tenax Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 1.67% of the stock of Tenax Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Tenax Therapeutics are expected to grow in the coming year, from ($7.43) to ($3.63) per share.Price to Book Value per Share RatioTenax Therapeutics has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Schaeffer’s ResearchJust Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.Yes! Show Me This Strategy About Tenax Therapeutics Stock (NASDAQ:TENX)Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.Read More TENX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TENX Stock News HeadlinesApril 15, 2024 | americanbankingnews.comShort Interest in Tenax Therapeutics, Inc. (NASDAQ:TENX) Rises By 33.5%April 9, 2024 | finance.yahoo.comTENX: 2023 Financial ResultsApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.April 9, 2024 | globenewswire.comTenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”March 28, 2024 | benzinga.comTenax Therapeutics: Q4 Earnings InsightsMarch 28, 2024 | msn.comTENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023March 28, 2024 | globenewswire.comTenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ResultsMarch 20, 2024 | bizjournals.comFormer public company CEO now leads RTP firmApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.March 12, 2024 | globenewswire.comTenax Therapeutics to Present at the 36th Annual Roth ConferenceFebruary 29, 2024 | globenewswire.comTenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024February 20, 2024 | finance.yahoo.comTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanFebruary 20, 2024 | globenewswire.comTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to LevosimendanFebruary 12, 2024 | finance.yahoo.comTENX: First Patient EnrolledFebruary 9, 2024 | bizjournals.comChapel Hill pharma pushing PHT treatment opens $9M stock offeringFebruary 8, 2024 | msn.comWhy Tenax Therapeutics (TENX) Stock Is Getting ObliteratedFebruary 8, 2024 | marketwatch.comTenax Therapeutics Shares Plummet Premarket After Stock OfferingFebruary 8, 2024 | markets.businessinsider.comTenax Therapeutics Announces Pricing Of About $9 Mln Offering Of Shares, Warrants; Stock Tanks 63%February 8, 2024 | finance.yahoo.comTenax Therapeutics Announces Pricing of Approximately $9 Million Public OfferingFebruary 8, 2024 | investorplace.comWhy Is Tenax Therapeutics (TENX) Stock Down 64% Today?February 8, 2024 | finance.yahoo.comTenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)February 7, 2024 | msn.comTenax Therapeutics Granted Patent for Heart Treatment DrugsFebruary 6, 2024 | marketwatch.comTenax Shares Surge After Acceptance of Patent ApplicationFebruary 6, 2024 | msn.comTenax surges after patent win for heart failure therapyFebruary 6, 2024 | finance.yahoo.comTenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)January 3, 2024 | benzinga.comTenax Therapeutics Stock (NASDAQ:TENX), Short Interest ReportJanuary 3, 2024 | finance.yahoo.comBreakeven On The Horizon For Tenax Therapeutics, Inc. (NASDAQ:TENX)See More Headlines Receive TENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenax Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2021Today4/24/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TENX CUSIPN/A CIK34956 Webwww.tenaxthera.com Phone919-855-2100Fax919-855-2133Employees5Year Founded1967Price Target and Rating Average Stock Price Target$480.00 High Stock Price Target$480.00 Low Stock Price Target$480.00 Potential Upside/Downside+13,383.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,710,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-65.79% Return on Assets-58.31% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$27.15 per share Price / Book0.13Miscellaneous Outstanding Shares1,960,000Free Float1,922,000Market Cap$6.98 million OptionableNot Optionable Beta2.25 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Christopher T. Giordano (Age 49)CEO, President & Director Comp: $644.77kDr. Stuart Rich M.D. (Age 74)Chief Medical Officer & Director Comp: $481.22kMr. Lawrence R. Hoffman CPA (Age 69)Esq., Interim Chief Financial Officer Mr. Doug RandallExecutive Vice President of Commercial & Business OperationsDr. Douglas HaySenior Vice President of Regulatory AffairsKey CompetitorsProtagenic TherapeuticsNASDAQ:PTIXYumanity TherapeuticsNASDAQ:YMTXAdial PharmaceuticalsNASDAQ:ADILClever LeavesNASDAQ:CLVRTrevenaNASDAQ:TRVNView All Competitors TENX Stock Analysis - Frequently Asked Questions Should I buy or sell Tenax Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tenax Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" TENX shares. View TENX analyst ratings or view top-rated stocks. What is Tenax Therapeutics' stock price target for 2024? 1 brokerages have issued 1 year price objectives for Tenax Therapeutics' shares. Their TENX share price targets range from $480.00 to $480.00. On average, they anticipate the company's stock price to reach $480.00 in the next year. This suggests a possible upside of 13,383.1% from the stock's current price. View analysts price targets for TENX or view top-rated stocks among Wall Street analysts. How have TENX shares performed in 2024? Tenax Therapeutics' stock was trading at $21.9680 at the beginning of 2024. Since then, TENX stock has decreased by 83.8% and is now trading at $3.56. View the best growth stocks for 2024 here. Are investors shorting Tenax Therapeutics? Tenax Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 49,000 shares, an increase of 33.5% from the March 15th total of 36,700 shares. Based on an average trading volume of 340,200 shares, the short-interest ratio is currently 0.1 days. Currently, 2.6% of the shares of the company are sold short. View Tenax Therapeutics' Short Interest. When is Tenax Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TENX earnings forecast. How were Tenax Therapeutics' earnings last quarter? Tenax Therapeutics, Inc. (NASDAQ:TENX) released its quarterly earnings data on Tuesday, November, 16th. The specialty pharmaceutical company reported ($240.00) EPS for the quarter, missing the consensus estimate of ($208.00) by $32.00. When did Tenax Therapeutics' stock split? Tenax Therapeutics's stock reverse split on Wednesday, January 3rd 2024. The 1-80 reverse split was announced on Wednesday, January 3rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of Tenax Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tenax Therapeutics investors own include Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), Inovio Pharmaceuticals (INO), Idera Pharmaceuticals (IDRA), NVIDIA (NVDA), SCYNEXIS (SCYX), Verastem (VSTM), Bank of Hawaii (BOH), Gilead Sciences (GILD) and AVEO Pharmaceuticals (AVEO). How do I buy shares of Tenax Therapeutics? Shares of TENX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TENX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
